Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics ("Protagonist") announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback